Intensity Therapeutics, Inc. (INTS) Stock Score, Valuation & Financial Research

Intensity Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for INTS

Intensity Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.55. These figures are a research snapshot, not a buy or sell recommendation.

What Intensity Therapeutics, Inc. does

Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Intensity Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel anti-cancer drug candidates, specifically utilizing its proprietary DfuseRx platform to create formulations for direct intratumoral injection.

Products and services

  • The company's primary product candidate is INT230-6, a novel formulation consisting of potent anti-cancer agents mixed with amphiphilic molecules designed to induce anti-cancer immune activation.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct its clinical trials and manage regulatory compliance. Source

Business relationships and partnerships

  • National Cancer Institute (NCI) — The company entered into a Collaboration Research and Development Agreement (CRADA) with the NCI to study the mechanism of action of INT230-6 and test the drug in various models. Source

Business strengths to evaluate

  • Proprietary DfuseRx discovery platform Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

INTS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.55
Market capitalization:
9.6M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -11.16M
Free cash flow:
USD -9.23M
Cash:
USD 9.53M
Total debt:
USD 95K
EPS:
USD -4.83

What stands out

  • Free cash flow is USD -9.23M, negative for the stored period.
  • The balance sheet shows USD 9.53M of cash versus USD 95K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 9.43M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for INTS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can INTS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is INTS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for INTS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of INTS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research INTS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.